Literature DB >> 16546302

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

Sanna-Kaisa Herukka1, Seppo Helisalmi, Merja Hallikainen, Susanna Tervo, Hilkka Soininen, Tuula Pirttilä.   

Abstract

BACKGROUND: The patients with mild cognitive impairment (MCI) have an elevated risk for Alzheimer's disease (AD). Especially the amnestic MCI is seen as prodrome of AD. Apolipoprotein E (APOE) epsilon4 allele, abnormal CSF Abeta42, Tau and phosphorylated Tau (phospho-Tau) levels are associated with elevated risk for AD.
METHODS: APOE genotyping was done by PCR based method and baseline CSF Abeta42, Tau and phospho-Tau were measured by ELISA from 60 controls and 79 MCI patients.
RESULTS: Thirty-three MCI patients developed dementia during an average of 3.5 years follow-up. CSF Abeta42 was decreased and Tau and phospho-Tau were increased in the progressive MCI patients. The APOE epsilon4 allele was more frequent in the progressive MCI patients. The APOE epsilon4 allele showed a dose dependent association o the Abeta42 levels in the progressive MCI patients and to all of the markers in controls.
CONCLUSIONS: Decreased CSF Abeta42 and elevated Tau or phospho-Tau together with APOE epsilon4 allele are highly predictive for the dementia in MCI patients with amnestic or executive symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546302     DOI: 10.1016/j.neurobiolaging.2006.02.001

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  38 in total

Review 1.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

2.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Authors:  Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A Saint Louis; Anders Wallin; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-09-24       Impact factor: 4.673

3.  Neuronal LR11/sorLA expression is reduced in mild cognitive impairment.

Authors:  Kristen L Sager; Joanne Wuu; Susan E Leurgans; Howard D Rees; Marla Gearing; Elliott J Mufson; Allan I Levey; James J Lah
Journal:  Ann Neurol       Date:  2007-12       Impact factor: 10.422

4.  Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.

Authors:  Elin S Blom; Vilmantas Giedraitis; Henrik Zetterberg; Hiroaki Fukumoto; Kaj Blennow; Bradley T Hyman; Michael C Irizarry; Lars-Olof Wahlund; Lars Lannfelt; Martin Ingelsson
Journal:  Dement Geriatr Cogn Disord       Date:  2009-05-07       Impact factor: 2.959

5.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 6.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

7.  Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease.

Authors:  Michael Ewers; Susanne Schmitz; Oskar Hansson; Cathal Walsh; Annette Fitzpatrick; David Bennett; Lennart Minthon; John Q Trojanowski; Leslie M Shaw; Yetunde O Faluyi; Bruno Vellas; Bruno Dubois; Kaj Blennow; Katharina Buerger; Stefan J Teipel; Michael Weiner; Harald Hampel
Journal:  Neurobiol Aging       Date:  2011-06-17       Impact factor: 4.673

8.  Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Michal Figurski; Els Coart; Kaj Blennow; Holly Soares; Adam J Simon; Piotr Lewczuk; Robert A Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2011-02-11       Impact factor: 17.088

9.  Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease.

Authors:  Claudia Plant; Stefan J Teipel; Annahita Oswald; Christian Böhm; Thomas Meindl; Janaina Mourao-Miranda; Arun W Bokde; Harald Hampel; Michael Ewers
Journal:  Neuroimage       Date:  2009-12-02       Impact factor: 6.556

10.  Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Authors:  Rilee H Robeson; Andrew M Siegel; Travis Dunckley
Journal:  Biomark Insights       Date:  2008-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.